Key Findings from Pasatru Clinical Trial in FOP @checkrare
Key Findings from Pasatru Clinical Trial in FOP  @checkrare
Uploaded November 2026 | Updated November 2026, 14 hours ago
Richard Keen, MD, PhD, Director of the Metabolic Bone Disease Centre at the Royal National Orthopaedic Hospital in London and global principal investigator of the OPTIMA trial, discusses positive 84-week results from the phase 3 OPTIMA trial extension, evaluating Pasatru (garetosmab-grts) in adults with fibrodysplasia ossificans progressiva (FOP).

View the full interview at checkrare.com/garetosmab-demonstrates-sustained-efficacy-in-adults-with-fibrodysplasia-ossificans-progressiva-fop
Key Findings from Pasatru Clinical Trial in FOPFDA CDER’s Accelerating Rare Disease Cures ProgramRevumenib + Chemotherapy in Newly Diagnosed AML With NPM1 Mutation: Phase 3 REVEAL-ND StudyRare Endocrine Exchange: Why This Conversation MattersA Family’s Journey with Prader-Willi SyndromeShowing Gratitude for Clinical Trial ParticipantsPriority Review for Dersimelagon in the Treatment of EPP and XLPPlasma Proteomics May Predict Disease Manifestations in ALSUltragenyx Gets $203M in Second Priority Review Voucher This Month | The CheckRare BriefPrimary Versus Severe IGF-1 DeficiencyHighlights from The Liver Meeting 2026Fabry Disease: How Well Does Your Medical Team Work Together and Understand Fabry Disease?
CheckRare |

Key Findings from Pasatru Clinical Trial in FOP

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER